Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries

References

• Penson DF. Quality of life after therapy for localized prostate cancer. Cancer J 2007;13:318–26.
   PubMed Web of Science ®Google Scholar
• Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–61.
   PubMed Web of Science ®Google Scholar
• Pardo Y, Guedea F, Aguiló F, Fernández P, Macías V, Mariño A, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 2010;28:4687–96.
   PubMed Web of Science ®Google Scholar
• Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368:436–45.
   PubMed Web of Science ®Google Scholar
• Namiki S, Arai Y. Health-related quality of life in men with localized prostate cancer. Int J Urol 2010;17:125–38.
   PubMed Web of Science ®Google Scholar
• Stensvold A, Dahl AA, Brennhovd B, Småstuen MC, Fosså SD, Lilleby W, et al. Bother problems in prostate cancer patients after curative treatment. Urol Oncol 2013;31:1067–78.
   PubMed Web of Science ®Google Scholar
• Steinsvik EA, Axcrona K, Dahl AA, Eri LM, Stensvold A, Fosså SD. Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother. BJU Int 2012;109:1366–74.
   PubMed Web of Science ®Google Scholar
• Wyler SF, Engeler DS, Steelentag W, Ries G, Schmid HP. Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer. Urol Int 2009;82:17–23.
   PubMed Web of Science ®Google Scholar
• Kyrdalen AE, Dahl AA, Hernes E, Småstuen MC, Fosså SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int 2013;111:221–32.
   PubMed Web of Science ®Google Scholar
• Resnick MJ, Penson DF. Quality of life with advanced metastatic prostate cancer. Urol Clin North Am2012;39:505–15.
   PubMed Web of Science ®Google Scholar
• Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56:899–905.
   PubMed Web of Science ®Google Scholar
• Chen RC, Chang P, Vetter RJ, Lukka H, Stokes WA, Sanda MG, et al. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst 2014;106:12.
   Google Scholar
• Hamoen EHJ, De Rooij M, Witjes JA, Barentsz JO, Rovers MM. Measuring health-related quality of life in men with prostate cancer: a systemic review of the most used questionnaires and their validity. Urol Oncol 2015;33:69.e19–e28.
   PubMed Web of Science ®Google Scholar
• Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46:1417–32.
   PubMed Web of Science ®Google Scholar
• Fosså SD, Dahl AA. Global quality of life after curative treatment for prostate cancer: what matters? A study among members of the Norwegian Prostate Cancer Patient Association. Clin Genitourin Cancer 2015;13:518–24.
   PubMed Web of Science ®Google Scholar
• Ware JE, Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995;33:264–79.
   Web of Science ®Google Scholar
• Drummond FJ, Kinnear H, O`Leary E, Donnelly, Gavin A Sharp L. Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. J Cancer Surviv 2015;9:72.
   Web of Science ®Google Scholar
• Bellardita L, Valdagni R, van den Bergh R, Randsdorp H, Repetto C, Venderbos LDF, et al. How does active surveillance for prostate cancer affect quality of life? A systematic review. Eur Urol 2015;67:637–45.
   PubMed Web of Science ®Google Scholar
• Carter G, Clover K, Britton B, Mitchell AJ, White M, McLeod N, et al. Wellbeing during active surveillance for localised prostate cancer: a systematic review of psychological morbidity and quality of life. Cancer Treat Rev 2015;41:46–60.
   PubMed Web of Science ®Google Scholar
• Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001;19:3385–91.
   PubMed Web of Science ®Google Scholar
• Kyrdalen AE, Dahl AA, Hernes E, Hem E, Fossa SD. Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs. Prostate 2010;70:1480–9.
   PubMed Web of Science ®Google Scholar
• Langston B, Armes J, Levy A, Tidey E, Ream E. The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer 2013;21:1761–71.
   PubMed Web of Science ®Google Scholar
• Kyrdalen AE, Dahl AA, Hernes E, Cvancarova M, Fossa SD. Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy. Prostate Cancer Prostatic Dis 2010;13:144–50.
   PubMed Web of Science ®Google Scholar
• Mols F, van de Poll-Franse LV, Vingerhoets AJJM, Hendrix A, Aaronson NK, Houterman S, et al. Long-term quality of life among Dutch prostate cancer survivors: results of a population-based study. Cancer 2006;107:2186–96.
   PubMed Web of Science ®Google Scholar
• Loge JH, Ekeberg O, Kaasa S. Fatigue in the general Norwegian population: normative data and associations. J Psychosom Res 1998;45:53–65.
   PubMed Web of Science ®Google Scholar
• Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009;55:62–75.
   PubMed Web of Science ®Google Scholar
• Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY, et al. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol 2015;33:2021–7.
   PubMed Web of Science ®Google Scholar